The broken line represents the cut-off value for each individual marker. pone.0018172.s002.tif (2.8M) GUID:?3B23BC1C-FA14-48C2-9055-8D3C5AE62786 Physique S3: Dooku1 Maximal changes in levels of single markers in Ulcerative colitis. Scatter plot comparing the level of the Rabbit Polyclonal to Cytochrome P450 4Z1 first sample and the sample with the maximal changes in quartile sum score during follow-up for each individual marker in Ulcerative colitis (UC) subjects. One dot represents one patient. gASCA: Dooku1 anti-antibodies, ACCA: anti-chitobioside carbohydrate IgA antibodies, ALCA: anti-laminaribioside carbohydrate IgG antibodies, AMCA: anti-mannobioside carbohydrate IgG antibodies, Anti-L: anti-laminarin carbohydrate antibody, Anti-C: anti-chitin carbohydrate antibody.(TIF) pone.0018172.s003.tif (2.8M) GUID:?CB490696-6B7D-4B82-A2D0-854CDF8A247E Table S1: Average of Dooku1 absolute standard deviations round the mean (Z-score).(TIFF) pone.0018172.s004.tiff (6.0M) GUID:?5AE2E838-DF85-4D2A-BB9F-3132408BBF74 Table S2: Common of absolute standard deviations round the mean (Z-score) and association with disease pheno- and NOD2 genotypes.(TIFF) pone.0018172.s005.tiff (6.0M) GUID:?FA0F1AEB-86A0-4EDD-AE74-F71411C607B1 Table S3: Correlation coefficients of the Z-score with disease parameters.(TIFF) pone.0018172.s006.tiff (6.0M) GUID:?4CF0E153-534D-44E8-B484-1E539BF89766 Table S4: Association of clinical phenotypes and genotypes with maximal level changes.(TIFF) pone.0018172.s007.tiff (6.0M) GUID:?CE0E58AE-B546-4EF0-A14B-030E88218182 Table S5: Number and distribution of CD subjects with antibody status changes.(TIFF) pone.0018172.s008.tiff (6.0M) GUID:?3E51DD5D-04D2-4C40-9F59-9EAC31DE6583 Table S6: Assosiation of clinical phenotypes and genotypes with status changes.(TIFF) pone.0018172.s009.tiff (6.0M) GUID:?53B6EE79-E3B3-4A25-9B4F-3B8BC8B75A65 Table S7: Longitudinal analysis of level changes inflicted by clinical situations.(TIFF) pone.0018172.s010.tiff (6.0M) GUID:?4E45F266-F3B8-4BAC-A440-4E75DC84582E Table S8: Validity of markers for association with disease phenotypes over time in individual patients.(TIFF) pone.0018172.s011.tiff (6.0M) GUID:?4B44F97B-C805-4E4B-A680-840C3D792FD6 Abstract Introduction Anti-glycan antibodies are a promising tool for differential diagnosis and disease stratification of patients with Crohn’s disease (CD). We longitudinally assessed level and status changes of anti-glycan antibodies over time in CD patients as well as determinants of this phenomenon. Methods 859 serum samples derived from a cohort of 253 inflammatory bowel disease (IBD) patients (207 CD, 46 ulcerative colitis (UC)) were tested for the presence of anti-laminarin (Anti-L), anti-chitin (Anti-C), anti-chitobioside (ACCA), anti-laminaribioside (ALCA), anti-mannobioside (AMCA) and anti-(gASCA) antibodies by ELISA. All patients experienced at least two and up to eleven serum samples taken during the disease course. Results Median follow-up time for CD was 17.4 Dooku1 months (Interquartile range (IQR) 8.0, 31.6 months) and for UC 10.9 months (IQR 4.9, 21.0 months). In a subgroup of CD subjects marked changes in the overall immune response (quartile sum score) and levels of individual markers were observed over time. The marker status (positive versus unfavorable) remained widely stable. Neither clinical phenotype nor NOD2 genotype was associated with the observed fluctuations. In a longitudinal analysis neither changes in disease activity nor CD behavior led to alterations in the levels of the glycan markers. The ability of the panel to discriminate CD from UC or its association with CD phenotypes remained stable during follow-up. In the serum of UC patients neither significant level nor status changes were observed. Conclusions While the levels of anti-glycan antibodies fluctuate in a subgroup of CD patients the antibody status is widely stable over time. Introduction The diagnosis of inflammatory bowel disease (IBD) and the differentiation between ulcerative colitis (UC) and Crohn’s disease (CD) is currently based on the combination of clinical, laboratory, radiological, endoscopic and histopathologic criteria [1]. However, in about 15% of colitis patients a definitive diagnosis cannot be made, a disease category termed indeterminate colitis (IC). In addition, CD is characterized by the frequent occurrence of complicated disease behavior, defined as fistulae or stenoses, and the need for CD-related surgery in a high proportion of patients [2], [3], [4]. Serological markers linked Dooku1 to CD, such as anti-(ASCA), anti-antibodies and antibodies against the bacterial flagellin cBir1 (Anti-cBir1) have been extensively investigated for.